BioSpace News Archive

Eagle Pharmaceuticals, Inc. announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care Annual Meeting being held September 8-10, 2023, in Alexandria, VA.

Johnson & Johnson announced updates to its financials and 2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced that the Company will participate at the following upcoming conferences.

Moderna, Inc. announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.

CRISPR Therapeutics announced that members of its senior management team are scheduled to participate in a fireside chat at Citi’s 18th Annual Biopharma Conference being held from September 6-7, 2023.

Serina Therapeutics, Inc., a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction.

60 Degrees Pharmaceuticals, Inc. announced the journal, New Microbes and New Infections, has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against Candida spp. in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of Rhizopus in mice.

Sensei Biotherapeutics, Inc., a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, announced that Company management will participate in the following investor conferences in September 2023.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.

LifeTech Scientific Corporation announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended 30 June 2023.